Focus on Anticoagulation Care

Back to articles

Apixaban outperforms warfarin in patients taking amiodarone

KEY POINT

An exploratory posthoc analysis of the ARISTOTLE trial concluded that in patients with atrial fibrillation (AF) who require amiodarone therapy, anticoagulation with apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) compared with warfarin  resulted in a lower risk of stroke or systemic embolism, death, and major bleeding.